Michael Israel, MD
Family Medicine · Lincoln, NENPI 1184907362
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $350,196 of the $375,082 with a category attached, or 93.4%. Kedplasma LLC accounts for 93.4% of it on its own, with 42 other manufacturers making up the rest. Reporting peaked in 2022 at $78,995 and has fallen 50.9% since, to $38,801 in 2025. Among family medicine clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 655 payments — averaging $572.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kedplasma LLC$350K
- Amgen$18K
- AbbVie$2K
- Novo Nordisk$787
- Bayer$671
- Astellas Pharma US Inc$356
- plus $3K from 37 others
What the payments were for
- Consulting fees$350,19693%
- Speaking & faculty fees$16,3634%
- Travel & lodging$5510%
- Food & beverage$7,9592%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$375,082 in reported general payments places this provider in the 95th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $58,720 |
| JardianceEmpagliflozin | 64 | $48,199 |
| XareltoRivaroxaban | 54 | $45,623 |
| VraylarCariprazine Hcl | 26 | $34,592 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $33,530 |
| TrulicityDulaglutide | 24 | $28,992 |
| KerendiaFinerenone | 33 | $25,921 |
| FarxigaDapagliflozin Propanediol | 45 | $24,435 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $21,147 |
| EliquisApixaban | 44 | $21,079 |
| RybelsusSemaglutide | 25 | $19,942 |
| LinzessLinaclotide | 16 | $18,416 |
| Tresiba Flextouch U-100Insulin Degludec | 45 | $17,094 |
| RexultiBrexpiprazole | 12 | $16,319 |
| Repatha SureclickEvolocumab | 12 | $14,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $787 | $78,66276 claims |
| AbbVieVraylar, Linzess, Namzaric, Synthroid | $2,352 | $63,154104 claims |
| Boehringer IngelheimJardiance | $148 | $48,19964 claims |
| Johnson & JohnsonXarelto | $90 | $45,62354 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere | $351 | $37,04464 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $114 | $30,82642 claims |
| Lilly USA, LLCTrulicity | $45 | $28,99224 claims |
| BayerKerendia | $671 | $25,92133 claims |
| PfizerEliquis | $276 | $21,07944 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $340 | $16,31912 claims |
| Astellas Pharma US IncMyrbetriq | $356 | $12,17720 claims |
| MerckJanuvia | $122 | $9,22514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Lincoln
- Randy KohlLincoln$67K
- Matthew GlennLincoln$17K
- Uma NookaLincoln$12K
- Kylie ParshallLincoln$12K
- Michael HuffmanLincoln$11K
- Gary van ErtLincoln$10K
- Kelly PierceLincoln$10K
- Charles KreshelLincoln$10K
- Mark ButlerLincoln$8K
- Eric JohnsonLincoln$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.